TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results